July 28, 2008 Mark A. Glickman Marlboro, NJ 07746 Re: Second Amendment to Employment Agreement Dear Mark:Employment Agreement • September 10th, 2008 • Oscient Pharmaceuticals Corp • Pharmaceutical preparations
Contract Type FiledSeptember 10th, 2008 Company IndustryThis Agreement effective July 28, 2008 amends the agreement between you and Oscient Pharmaceuticals Corporation (“OSCIENT”) dated as of August 16, 2007, subsequently amended August 22, 2007, regarding the terms and conditions of your employment (the “Employment Agreement”). Capitalized terms in this Agreement shall have the meaning ascribed to them in the Employment Agreement unless otherwise expressly provided in this Agreement.
Re: First Amendment to Employment AgreementEmployment Agreement • September 10th, 2008 • Oscient Pharmaceuticals Corp • Pharmaceutical preparations
Contract Type FiledSeptember 10th, 2008 Company IndustryThis Agreement effective August 22, 2007 amends the agreement between you and Oscient Pharmaceuticals Corporation (“OSCIENT”) dated as of August 16, 2007 regarding the terms and conditions of your employment (the “Employment Agreement”). Capitalized terms in this Agreement shall have the meaning ascribed to them in the Employment Agreement unless otherwise expressly provided in this Agreement.
AGREEMENTAgreement • September 10th, 2008 • Oscient Pharmaceuticals Corp • Pharmaceutical preparations • Massachusetts
Contract Type FiledSeptember 10th, 2008 Company Industry Jurisdiction
REVENUE INTERESTS ASSIGNMENT AGREEMENT Dated as of July 21, 2006 and Restated as of August 18, 2006 between OSCIENT PHARMACEUTICALS CORPORATION, GUARDIAN II ACQUISITION CORPORATION and PAUL ROYALTY FUND HOLDINGS IIRevenue Interests Assignment Agreement • September 10th, 2008 • Oscient Pharmaceuticals Corp • Pharmaceutical preparations • New York
Contract Type FiledSeptember 10th, 2008 Company Industry JurisdictionThis REVENUE INTERESTS ASSIGNMENT AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of July 21, 2006 by and among Oscient Pharmaceuticals Corporation, a Massachusetts corporation (the “Company”), Guardian II Acquisition Corporation, a wholly-owned Delaware subsidiary of the Company, and Paul Royalty Fund Holdings II, a California general partnership (“PRF”).